Evopoint Biosciences Co. Ltd. has patented 2-acylglycerol O-acyltransferase 2 (MGAT2, MOGAT2) inhibitors. They are described as potentially useful for the treatment of obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, diabetes and arteriosclerosis.
Evopoint Biosciences Co. Ltd. has obtained clinical trial clearance in China for XNW-34017, an oral protein degrader that targets Aurora kinase A (AURKA) while simultaneously degrading MYC.
Evopoint Biosciences Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an Aurora kinase A (AURKA; ARK1)-targeting moiety through a linker potentially useful for the treatment of cancer.
In yet another China antibody-drug conjugate (ADC) deal, Astellas Pharma Inc. is inlicensing a phase I/II ADC targeting Claudin 18.2 from Evopoint Biosciences Co. Ltd. for up to $1.34 billion.
In yet another China antibody-drug conjugate (ADC) deal, Astellas Pharma Inc. is inlicensing a phase I/II ADC targeting Claudin 18.2 from Evopoint Biosciences Co. Ltd. for up to $1.34 billion.
DNA damage repair enzymes are interesting targets in cancer, since genomic instability and DNA repair defects are important cancer cell hallmarks. Poly (ADP-ribose) glycohydrolase (PARG) is the dominant eliminator of PARylation in the cell, the activity of which prevents excessive accumulation of PARylation, and promotes the dissociation of repair proteins, as well as ensuring the smooth completion of DNA repair process.
Evopoint Biosciences Co. Ltd. has synthesized probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) inhibitors reported to be useful for the treatment of cancer.
Hematopoietic progenitor kinase 1 (HPK1) is a serine/threonine kinase restricted to the hematopoietic compartment that plays a crucial role in cellular proliferation, apoptosis and modulation of the antitumor immune response. In mice, HPK1 deficiency is associated with enhanced immune response, and thus, HPK1 is considered a novel target for cancer immunotherapy.
Ammax Bio Inc. has entered into an exclusive option with Evopoint Biosciences Co. Ltd. for a worldwide license, excluding Greater China, for the development and commercialization of a novel antibody-drug conjugate (ADC) for treating solid tumors.
